Effects of hepatic impairment on the pharmacokinetics of nilotinib: An open-label, single-dose, parallel-group study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Effects of hepatic impairment on the pharmacokinetics of nilotinib: An open-label, single-dose, parallel-group study

Published:2009-01 Issue: Volume:31 Page:2459-2469
ISSN:0149-2918
Container-title:Clinical Therapeutics
language:en
Short-container-title:Clinical Therapeutics

Author:

Yin Ophelia Q.P.,Gallagher Neil,Tanaka Chiaki,Fisher Deirdre,Sethuraman Venkat,Zhou Wei,Lin Tsu-Han,Heuman Douglas,Schran Horst

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmacology

Reference20 articles.

1. AMN107 (nilotinib): A novel and selective inhibitor of BCR-ABL;Weisberg;Br J Cancer,2006

2. AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells;Verstovsek;Cancer,2005

3. AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia;Golemovic;Clin Cancer Res,2005

4. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl [published correction appears in Cancer Cell. 2005;7:399];Weisberg;Cancer Cell,2005

5. Tasigna for chronic and accelerated phase Philadelphia chromosome-positive chronic myelogenous leukemia resistant to or intolerant of imatinib;Hazarika;Clin Cancer Res,2008

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Re‐discover the value of protein binding assessments in hepatic and renal impairment studies and its contributions in drug labels and dose decisions;Clinical and Translational Science;2024-05

2. Clinical pharmacokinetics and drug–drug interactions of tyrosine-kinase inhibitors in chronic myeloid leukemia: A clinical perspective;Critical Reviews in Oncology/Hematology;2024-03

3. Validation of an LC-MS/MS assay for rapid and simultaneous quantification of 21 kinase inhibitors in human plasma and serum for therapeutic drug monitoring;Journal of Chromatography B;2023-09

4. Evaluation and Clarification of Enterohepatic Interactions in Pharmacokinetics;YAKUGAKU ZASSHI;2023-02-01

5. Pharmacokinetics, Bioequivalence, and Safety Studies of a Generic Selective Tyrosine Kinase Inhibitor Nilotinib Capsule Versus a Branded Product in Healthy Chinese Volunteers;Clinical Pharmacology in Drug Development;2022-07-28

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3